Peter Fernandes
Chairman bei The Pulmonary Vascular Research Institute
Vermögen: 1 940 $ am 31.03.2024
Profil
Peter Fernandes is currently the Co-Chairman at The Pulmonary Vascular Research Institute.
He previously worked as the Vice President-Global Regulatory Affairs at Ikaria, Inc. from 2012 to 2015, Head-Regulatory Affairs & Quality Assurance at OptiNose, Inc. from 2010 to 2012, VP-Regulatory Affairs & Quality Assurance at ALTANA Pharma US, Inc. from 2005 to 2007, and Vice President-US Drug Regulatory Affairs at Novartis Pharmaceuticals AG from 2007 to 2010.
He is also currently the Chief Executive, Financial & Accounting Officer at Bellerophon Therapeutics, Inc. starting from 2015.
Mr. Fernandes received his graduate degree from The Grant Government Medical College in 1982 and his undergraduate degree from Principal K.
M.
Kundnani College of Pharmacy.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.10.2023 | 34 649 ( 0,28% ) | 1 940 $ | 31.03.2024 |
Aktive Positionen von Peter Fernandes
| Unternehmen | Position | Beginn |
|---|---|---|
The Pulmonary Vascular Research Institute
 The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Chairman | - |
Ehemalige bekannte Positionen von Peter Fernandes
| Unternehmen | Position | Ende |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Chief Executive Officer | 15.11.2023 |
| IKARIA, INC. | General Counsel | 01.05.2015 |
| OPTINOSE, INC. | General Counsel | 01.09.2012 |
| Novartis Pharmaceuticals AG | Corporate Officer/Principal | 01.10.2010 |
ALTANA Pharma US, Inc.
 ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | General Counsel | 01.10.2007 |
Ausbildung von Peter Fernandes
| The Grant Government Medical College | Graduate Degree |
| Principal K. M. Kundnani College of Pharmacy | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
ALTANA Pharma US, Inc.
ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | Health Technology |
The Pulmonary Vascular Research Institute
The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Commercial Services |
| Novartis Pharmaceuticals AG |
